Parkash S. Gill
Affiliations: | University of Southern California, Los Angeles, CA, United States |
Area:
Oncology, Molecular BiologyGoogle:
"Parkash Gill"Children
Sign in to add traineeRam K. Subramanyan | grad student | 2006 | USC |
Jeffrey S. Scehnet | grad student | 2010 | USC |
Xiuqing Li | grad student | 2011 | USC |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
De Zoysa P, Liu J, Toubat O, et al. (2020) Delta-like ligand-4 mediated Notch signaling controls proliferation of second heart field progenitor cells by regulating Fgf8 expression. Development (Cambridge, England) |
Li GX, Zhang S, Liu R, et al. (2020) Tetraspanin18 regulates angiogenesis through VEGFR2 and Notch pathways. Biology Open |
Hanna DL, Iqbal S, Habib D, et al. (2020) A phase Ib study of sEphB4-HSA combined with first-line chemotherapy in patients (pts) with advanced pancreatic (PC) and biliary cancers (BC). Journal of Clinical Oncology. 38: 4640-4640 |
Sagar V, Vatapalli R, Lysy B, et al. (2019) EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death & Disease. 10: 801 |
Sadeghi S, Li G, Siddiqi I, et al. (2019) EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC). Journal of Clinical Oncology. 37: 275-275 |
Li GX, Ma B, Krasnoperov VG, et al. (2019) Abstract 3139: EphB4-EphrinB2 receptor-ligand are downstream effectors and novel targets of PTEN deficient prostate cancer Cancer Research |
Thomas JS, Lenz H, Iqbal S, et al. (2018) A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA). Journal of Clinical Oncology. 36: 285-285 |
McDaniel NK, Cummings CT, Brand TM, et al. (2018) Abstract A140: MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents Molecular Cancer Therapeutics. 17 |
Merchant AA, Jorapur A, McManus A, et al. (2017) EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 1: 1635-1644 |
Randolph ME, Cleary MM, Bajwa Z, et al. (2017) EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. Plos One. 12: e0183161 |